[go: up one dir, main page]

MX2019003098A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2019003098A
MX2019003098A MX2019003098A MX2019003098A MX2019003098A MX 2019003098 A MX2019003098 A MX 2019003098A MX 2019003098 A MX2019003098 A MX 2019003098A MX 2019003098 A MX2019003098 A MX 2019003098A MX 2019003098 A MX2019003098 A MX 2019003098A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
component
glycopyrrolate
hfa
difluoroethane
Prior art date
Application number
MX2019003098A
Other languages
English (en)
Other versions
MX387723B (es
Inventor
James Noakes Timothy
Corr Stuart
Original Assignee
Mexichem Fluor Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59997386&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019003098(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB1615917.0A external-priority patent/GB2558191A/en
Priority claimed from GBGB1620519.7A external-priority patent/GB201620519D0/en
Application filed by Mexichem Fluor Sa De Cv filed Critical Mexichem Fluor Sa De Cv
Publication of MX2019003098A publication Critical patent/MX2019003098A/es
Publication of MX387723B publication Critical patent/MX387723B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una composición farmacéutica. La composición comprende: (i) un componente de fármaco que comprende al menos una sal aceptable desde el punto de vista farmacéutico de glicopirrolato; y (ii) un componente propulsor que comprende 1,1-difluoroetano (HFA-152a).
MX2019003098A 2016-09-19 2017-09-18 Composición farmacéutica que comprende bromuro de glicopirronio, propionato de fluticasona y 1,1-difluoroetano. MX387723B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1615917.0A GB2558191A (en) 2016-09-19 2016-09-19 Pharmaceutical composition
GBGB1620519.7A GB201620519D0 (en) 2016-12-02 2016-12-02 Pharmaceutical composition
PCT/GB2017/052761 WO2018051130A1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
MX2019003098A true MX2019003098A (es) 2019-08-01
MX387723B MX387723B (es) 2025-03-18

Family

ID=59997386

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2021009476A MX392213B (es) 2016-09-19 2017-09-18 Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
MX2019003098A MX387723B (es) 2016-09-19 2017-09-18 Composición farmacéutica que comprende bromuro de glicopirronio, propionato de fluticasona y 1,1-difluoroetano.
MX2021009475A MX2021009475A (es) 2016-09-19 2019-03-15 Composiciones farmaceuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021009476A MX392213B (es) 2016-09-19 2017-09-18 Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021009475A MX2021009475A (es) 2016-09-19 2019-03-15 Composiciones farmaceuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.

Country Status (19)

Country Link
US (9) US10888546B2 (es)
EP (4) EP3915555B1 (es)
JP (3) JP6781829B2 (es)
KR (2) KR102277635B1 (es)
CN (4) CN109789126B (es)
AU (3) AU2017328907B2 (es)
CA (1) CA3037092C (es)
CO (1) CO2019002556A2 (es)
ES (4) ES2968212T3 (es)
GE (1) GEP20217239B (es)
IL (1) IL265360B2 (es)
MX (3) MX392213B (es)
MY (1) MY202069A (es)
PE (1) PE20191043A1 (es)
PH (1) PH12019500579B1 (es)
SA (1) SA519401336B1 (es)
UA (1) UA123919C2 (es)
WO (1) WO2018051130A1 (es)
ZA (1) ZA201902053B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
HK1248570A1 (zh) 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
CN113069417A (zh) * 2016-09-19 2021-07-06 墨西哥氟石股份公司 药物组合物
PE20191043A1 (es) 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica
US20190374519A1 (en) * 2016-09-19 2019-12-12 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
US11260052B2 (en) * 2016-09-19 2022-03-01 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
JP6781828B2 (ja) * 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
KR102041239B1 (ko) * 2017-02-22 2019-11-06 도레이첨단소재 주식회사 이형필름
WO2019104191A1 (en) * 2017-11-21 2019-05-31 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3801479A1 (en) * 2018-06-07 2021-04-14 Kindeva Drug Delivery L.P. Fluticasone and vilanterol formulation and inhaler
GB2584686A (en) * 2019-06-11 2020-12-16 Mexichem Fluor Sa De Cv Methods
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
GB2586477A (en) * 2019-08-20 2021-02-24 Mexichem Fluor Sa De Cv Composition and method
PE20221867A1 (es) 2020-01-28 2022-12-02 Chiesi Farm Spa Inhaladores de dosis medida presurizada que comprenden una formulacion farmaceutica amortiguada
AU2021223587A1 (en) 2020-02-20 2022-09-29 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
CN111624292A (zh) * 2020-07-10 2020-09-04 武汉伯瑞恒医药科技有限公司 一种测定血清中茚达特罗格隆溴铵浓度的方法
CN112051346A (zh) * 2020-09-24 2020-12-08 珠海瑞思普利生物制药有限公司 一种同时测定茚达特罗和格隆溴铵含量的hplc方法
MX2024002496A (es) * 2021-09-08 2024-03-15 Kindeva Drug Delivery Lp Propulsores para agentes anticolinergicos en inhaladores de dosis medida presurizados.
EP4673151A1 (en) * 2022-03-01 2026-01-07 Kindeva Drug Delivery L.P. Metered dose inhalers and high-dose suspensions

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
GB9024366D0 (en) 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US6123924A (en) 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
FR2718437B1 (fr) * 1994-04-11 1996-06-28 Solvay Procédé de séparation du 1,1-difluoroéthane de ses mélanges avec le fluorure d'hydrogène.
CN1088580C (zh) 1994-12-22 2002-08-07 阿斯特拉公司 气溶胶药物制剂
KR100589926B1 (ko) 1997-09-29 2006-06-15 넥타르 테라퓨틱스 천공된 미립자 및 사용 방법
US6103266A (en) 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
CN1158996C (zh) 1998-07-24 2004-07-28 杰格研究股份公司 药用气溶胶制剂
DK1102579T3 (da) 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
DE60019167T2 (de) 1999-12-24 2006-05-11 Glaxo Group Ltd., Greenford Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
CN1144582C (zh) 2000-11-28 2004-04-07 中国药科大学 治疗呼吸系统疾病的无氟里昂药用气雾剂
CN1216600C (zh) 2002-04-24 2005-08-31 信谊药厂 盐酸左旋沙丁胺醇气雾剂及制备工艺
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
CA2496699C (en) 2002-08-29 2012-07-17 Cipla Ltd. Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
CA2510043A1 (en) 2002-12-16 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing hfc solution formulations
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
DK1713473T3 (da) 2004-02-06 2013-06-17 Meda Pharma Gmbh & Co Kg Kombination af anticholinergika og glucocorticoider til langtidsbehandling af astma og COPD
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
US20060018840A1 (en) 2004-06-28 2006-01-26 Nektar Therapeutics Aerosolizable formulation comprising nicotine
ES2259915B1 (es) 2005-03-15 2007-12-16 Laboratorio Aldo-Union, S.A. Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion.
WO2007020204A2 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
DE102006017320A1 (de) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL2435024T3 (pl) 2009-05-29 2017-01-31 Pearl Therapeutics, Inc. Dostarczanie substancji czynnych do dróg oddechowych oraz powiązane sposoby i systemy
DK2515855T6 (da) * 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
PT2515854E (pt) 2009-12-23 2014-05-27 Chiesi Farma Spa Formulação de aerossol para dpoc
EP2749280A3 (en) * 2011-02-17 2014-08-20 Cipla Limited Combination of glycopyrronium and formoterol
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
JP2016503390A (ja) 2012-10-23 2016-02-04 シプラ・リミテッド 医薬組成物
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
CN105392471A (zh) 2013-05-22 2016-03-09 珍珠治疗公司 用于呼吸递送三种或更多种活性剂的组合物、方法和系统
TN2016000262A1 (en) 2013-12-30 2017-10-06 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination.
CA2935305C (en) 2013-12-30 2022-07-12 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
EP3383366B2 (en) 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
JP6781828B2 (ja) * 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
PE20191043A1 (es) * 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica

Also Published As

Publication number Publication date
IL265360A (en) 2019-05-30
US11103480B2 (en) 2021-08-31
IL265360B (en) 2022-10-01
PH12019500579B1 (en) 2024-02-21
JP2020114826A (ja) 2020-07-30
US20210322378A1 (en) 2021-10-21
ZA201902053B (en) 2024-10-30
PH12019500579A1 (en) 2019-08-19
EP3515432B1 (en) 2021-08-25
CA3037092C (en) 2022-06-21
US11826349B2 (en) 2023-11-28
JP7041703B2 (ja) 2022-03-24
CN114272238A (zh) 2022-04-05
US20210401800A1 (en) 2021-12-30
US20200016119A1 (en) 2020-01-16
US20240050404A1 (en) 2024-02-15
EP3610871B1 (en) 2023-11-08
IL265360B2 (en) 2023-02-01
ES2968212T3 (es) 2024-05-08
US20190255018A1 (en) 2019-08-22
PE20191043A1 (es) 2019-08-06
CN114515284A (zh) 2022-05-20
US10888546B2 (en) 2021-01-12
ES2968453T3 (es) 2024-05-09
EP3610871A1 (en) 2020-02-19
ES2892673T3 (es) 2022-02-04
US11179366B2 (en) 2021-11-23
AU2017328907B2 (en) 2020-04-09
MX2021009475A (es) 2021-09-08
US11642330B2 (en) 2023-05-09
SA519401336B1 (ar) 2024-05-30
AU2021205045A1 (en) 2021-08-12
AU2020202626A1 (en) 2020-05-14
CN114712338A (zh) 2022-07-08
BR112019005133A2 (pt) 2019-06-04
MX2021009476A (es) 2022-05-11
KR102277635B1 (ko) 2021-07-19
AU2021205045B2 (en) 2022-08-25
CN109789126B (zh) 2022-08-05
MX392213B (es) 2025-03-21
CN109789126A (zh) 2019-05-21
AU2017328907A1 (en) 2019-04-04
US20210322377A1 (en) 2021-10-21
EP3915555B1 (en) 2023-06-28
UA123919C2 (uk) 2021-06-23
CO2019002556A2 (es) 2020-02-18
AU2021205045C1 (en) 2022-12-22
MY202069A (en) 2024-03-31
CA3037092A1 (en) 2018-03-22
ES2957459T3 (es) 2024-01-19
JP6781829B2 (ja) 2020-11-04
JP2022065106A (ja) 2022-04-26
NZ752430A (en) 2021-02-26
JP2019529428A (ja) 2019-10-17
EP3607936B1 (en) 2023-11-08
EP3607936A1 (en) 2020-02-12
GEP20217239B (en) 2021-03-25
MX387723B (es) 2025-03-18
EP3515432A1 (en) 2019-07-31
EP3915555A1 (en) 2021-12-01
US20240050405A1 (en) 2024-02-15
US11690823B2 (en) 2023-07-04
JP7228726B2 (ja) 2023-02-24
AU2020202626B2 (en) 2021-08-05
WO2018051130A1 (en) 2018-03-22
KR20190063467A (ko) 2019-06-07
KR20210089273A (ko) 2021-07-15
US20200016120A1 (en) 2020-01-16
US20210322379A1 (en) 2021-10-21
US11826348B2 (en) 2023-11-28

Similar Documents

Publication Publication Date Title
CO2019002556A2 (es) Composición farmacéutica
MX2019003099A (es) Composicion farmaceutica.
MX2022007350A (es) Derivados de pirazolilo utiles como agentes anticancerigenos.
MX2019003105A (es) Composicion farmaceutica.
MX386777B (es) Composición farmacéutica que comprende un compuesto de tiotropio.
MX2023011675A (es) Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia.
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
CO2019002555A2 (es) Composición farmacéutica
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
CL2018001407A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
PE20241347A1 (es) MODULAR LA EXPRESION DE APOLIPOPROTEINA (a)
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CL2022001353A1 (es) Inhibidores de egfr
CL2018001408A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
CL2020002199A1 (es) Compuesto de anillo de metillactama y uso farmacéutico del mismo.
MX2020011367A (es) Compuesto oxo-sustituido.
AR121477A1 (es) Compuestos y métodos para el tratamiento de infecciones fúngicas
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
EA201990506A1 (ru) Фармацевтическая композиция
WO2019190427A3 (en) The immediate release combination comprising raloxifene and at least one antipsychotic agent
CO2021018010A2 (es) Composiciones de diclorfenamida y métodos de uso
CL2018000359A1 (es) Fenoxiacetamidas apareadas novedosas
EA202090298A1 (ru) Способы лечения муковисцидоза